Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Genmab
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Toray Industries, Inc
NGM Biopharmaceuticals, Inc
Mayo Clinic
Eucure (Beijing) Biopharma Co., Ltd
Immodulon Therapeutics Ltd
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Washington University School of Medicine
Northwestern University
Northwestern University
Fred Hutchinson Cancer Center
University College, London
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Charite University, Berlin, Germany